
    
      Due to the logistical considerations, UCB has decided to consolidate the Phase II and Phase
      III open-label extension trials. Subjects completing this study will be offered the option of
      continuing to receive epratuzumab through participation in Phase III open-label extension
      study SL0012 (NCT01408576).
    
  